Cansino Biologics Inc. (6185)

Hong Kong
44.55
-0.65(-1.44%)
  • Volume:
    418,006
  • Bid/Ask:
    44.50/44.55
  • Day's Range:
    43.00 - 45.40

6185 Overview

Prev. Close
45.2
Day's Range
43-45.4
Revenue
4.85B
Open
43
52 wk Range
42.4-266.8
EPS
4
Volume
418,006
Market Cap
21.17B
Dividend (Yield)
0.9373
(2.10%)
Average Vol. (3m)
1,219,559
P/E Ratio
12.34
Beta
0.082
1-Year Change
-83.8%
Shares Outstanding
246,949,899
Next Earnings Date
Oct 27, 2022
What is your sentiment on Cansino Biologics?
or
Market is currently closed. Voting is open during market hours.

Cansino Biologics Inc. News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Cansino Biologics Inc. Analysis

Cansino Biologics Inc. Company Profile

Cansino Biologics Inc. Company Profile

Employees
0
Market
Hong Kong

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • UBS Cuts CANSINOBIO-B TP to $200, Rating Buy
    0
    • UBS Drops CANSINOBIO-B TP to $216, Rated Buy
      0
      • 1st TP 350 gogogo
        0
        • UBS Trims CANSINOBIO-B TP to $400; Rated Buy
          0
          • It's time..
            0
        • Time to buy again
          0
          • Biotech stocks will go strong
            0
        • 🚀🚀🚀🚀🚀🚀🚀🚀
          0
          • When announce efficacy?
            0
            • Buy
              0
              • Where can i trade this
                0
                • flying soon from 182 to 300 real soon
                  0
                  • You did tell us so!
                    0